Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective, multicenter, randomized, controlled trial evaluating the performance of a novel combination powder vs hemostatic matrix in cardiothoracic operations.
Dang NC, Ardehali A, Bruckner BA, Parrino PE, Gillen DL, Hoffman RW, Spotnitz R, Cavoores S, Shorn IJ, Manson RJ, Spotnitz WD. Dang NC, et al. Among authors: hoffman rw. J Card Surg. 2020 Feb;35(2):313-319. doi: 10.1111/jocs.14376. Epub 2019 Nov 25. J Card Surg. 2020. PMID: 31763732 Free PMC article. Clinical Trial.
Evaluation of the safety and efficacy of a new hemostatic powder using a quantitative surface bleeding severity scale.
Ardehali A, Spotnitz WD, Hoffman RW, Olson SA, Bochicchio GV, Hermann MC, Lakshman S, Dang NC, Centis V, Gillen DL, Schorn IJ, Spotnitz RH; Advanced Powder Investigators Group (APIG). Ardehali A, et al. Among authors: hoffman rw. J Card Surg. 2019 Jan;34(1):50-62. doi: 10.1111/jocs.13982. Epub 2019 Jan 10. J Card Surg. 2019. PMID: 30629770 Clinical Trial.
SPOT GRADE II: Clinical Validation of a New Method for Reproducibly Quantifying Surgical Wound Bleeding: Prospective, Multicenter, Multispecialty, Single-Arm Study.
Gaizo DJD, Spotnitz WD, Hoffman RW, Hermann MC, Sher LS, Spotnitz RH, Genyk YS, Schorn IJ, Gillen DL, White BL, Miller BG, Manson RJ. Gaizo DJD, et al. Among authors: hoffman rw. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936340. doi: 10.1177/1076029620936340. Clin Appl Thromb Hemost. 2020. PMID: 32703005 Free PMC article.
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Dörner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER, Higgs RE, Rocha G, Crowe B, Benschop RJ, Byers NL, Silk ME, de Bono S, Fantini D, Hoffman RW. Dörner T, et al. Among authors: hoffman rw. Lupus Sci Med. 2020 Oct;7(1):e000424. doi: 10.1136/lupus-2020-000424. Lupus Sci Med. 2020. PMID: 33037080 Free PMC article. Clinical Trial.
Baricitinib for systemic lupus erythematosus - Authors' reply.
Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW. Wallace DJ, et al. Among authors: hoffman rw. Lancet. 2019 Feb 2;393(10170):402-403. doi: 10.1016/S0140-6736(18)32749-1. Lancet. 2019. PMID: 30712893 No abstract available.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Wallace DJ, et al. Among authors: hoffman rw. Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Lancet. 2018. PMID: 30043749 Clinical Trial.
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
Hoffman RW, Merrill JT, Alarcón-Riquelme MM, Petri M, Dow ER, Nantz E, Nisenbaum LK, Schroeder KM, Komocsar WJ, Perumal NB, Linnik MD, Airey DC, Liu Y, Rocha GV, Higgs RE. Hoffman RW, et al. Arthritis Rheumatol. 2017 Mar;69(3):643-654. doi: 10.1002/art.39950. Arthritis Rheumatol. 2017. PMID: 27723281 Free PMC article. Clinical Trial.
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ. Isenberg DA, et al. Among authors: hoffman rw. Ann Rheum Dis. 2016 Feb;75(2):323-31. doi: 10.1136/annrheumdis-2015-207653. Epub 2015 Sep 3. Ann Rheum Dis. 2016. PMID: 26338095 Clinical Trial.
91 results